- Home
- EBMT vs SKYE Comparison
EBMT vs SKYE Comparison
Compare EBMT & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EBMT | SKYE |
|---|---|---|
| Founded | 1922 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.0M | 44.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | EBMT | SKYE |
|---|---|---|
| Price | $19.96 | $0.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.75 |
| AVG Volume (30 Days) | 42.3K | ★ 299.5K |
| Earning Date | 01-27-2026 | 11-10-2025 |
| Dividend Yield | ★ 2.92% | N/A |
| EPS Growth | ★ 58.15 | N/A |
| EPS | ★ 1.72 | N/A |
| Revenue | ★ $87,531,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.26 | N/A |
| P/E Ratio | $11.53 | ★ N/A |
| Revenue Growth | ★ 9.36 | N/A |
| 52 Week Low | $14.35 | $0.93 |
| 52 Week High | $20.22 | $5.75 |
Technical Indicators
Market Signals| Indicator | EBMT | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 85.73 | 31.56 |
| Support Level | $19.40 | $1.04 |
| Resistance Level | $16.50 | $1.27 |
| Average True Range (ATR) | 0.43 | 0.10 |
| MACD | 0.24 | 0.00 |
| Stochastic Oscillator | 92.88 | 1.48 |
Price Performance
Historical ComparisonAbout EBMT Eagle Bancorp Montana Inc.
Eagle Bancorp Montana Inc operates as a bank holding company. It provides loan and deposit services. The company focuses on residential loans, commercial real estate loans, commercial loans, consumer loans, and home equity loan products. The bank also offers deposit accounts which include checking, savings, money market, individual retirement accounts, and certificates of deposit accounts. It is a diversified lender with a focus on residential mortgage loans, commercial real estate mortgage loans, commercial business loans, agricultural loans, and second mortgage/home equity loan products.
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.